Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 71
Filter
1.
Aten Primaria ; 56(7): 102922, 2024 Apr 06.
Article in Spanish | MEDLINE | ID: mdl-38583414

ABSTRACT

The care of migrant patients includes initial screening and lifelong monitoring, highlighting the importance of preventing and tracking chronic, communicable and non-communicable diseases. The prevalence of hypertension, diabetes mellitus, dyslipidemia, and obesity varies by ethnicity, influenced by genetic factors, lifestyle, and socio-economic status. Preventive measures, health promotion, and risk factor identification are crucial. Chronic communicable diseases may manifest years after transmission, underscoring the necessity of primary care screening, especially for populations from endemic or high-risk areas. Imported skin lesions are a common reason for consultation among migrant and traveller patients. Their ethiology is varied, ranging from common conditions such as scabies, mycoses, and urticaria to tropical dermatoses like filariasis and leprosy.

2.
Rev Gastroenterol Mex (Engl Ed) ; 89(1): 121-143, 2024.
Article in English | MEDLINE | ID: mdl-38580493

ABSTRACT

INTRODUCTION: Gastroesophageal reflux disease (GERD) is very prevalent in the general population, with a broad spectrum of clinical manifestations, requiring accurate diagnosis and treatment. AIM: The aim of this expert review is to establish good clinical practice recommendations for the diagnosis and personalized treatment of GERD. METHODS: The good clinical practice recommendations were produced by a group of experts in GERD, members of the Asociación Mexicana de Gastroenterología (AMG), after carrying out an extensive review of the published literature and discussing each recommendation at a face-to-face meeting. This document does not aim to be a clinical practice guideline with the methodology such a document requires. RESULTS: Fifteen experts on GERD formulated 27 good clinical practice recommendations for recognizing the symptoms and complications of GERD, the rational use of diagnostic tests and medical treatment, the identification and management of refractory GERD, the overlap with functional disorders, endoscopic and surgical treatment, and GERD in the pregnant woman, older adult, and the obese patient. CONCLUSIONS: An accurate diagnosis of GERD is currently possible, enabling the prescription of a personalized treatment in patients with this condition. The goal of the good clinical practice recommendations by the group of experts from the AMG presented in this document is to aid both the general practitioner and specialist in the process of accurate diagnosis and treatment, in the patient with GERD.


Subject(s)
Gastroesophageal Reflux , Female , Pregnancy , Humans , Aged , Gastroesophageal Reflux/diagnosis , Gastroesophageal Reflux/therapy , Endoscopy
3.
Arch. bronconeumol. (Ed. impr.) ; 56(supl.2): 261-270, jul. 2020. ilus, tab
Article in Spanish | IBECS | ID: ibc-192469

ABSTRACT

La enfermedad por coronavirus 2019 (COVID-19) es una infección del tracto respiratorio causada por un nuevo coronavirus emergente que se reconoció por primera vez en Wuhan, China, en diciembre de 2019. Actualmente la Organización Mundial de la Salud (OMS) ha definido la infección como pandemia y existe una situación de emergencia sanitaria y social para el manejo de esta nueva infección. Mientras que la mayoría de las personas con COVID-19 desarrollan solo una enfermedad leve o no complicada, aproximadamente el 14% desarrollan una enfermedad grave que requiere hospitalización y oxígeno, y el 5% pueden requerir ingreso en una Unidad de Cuidados Intensivos. En casos severos, COVID-19 puede complicarse por el síndrome de dificultad respiratoria aguda (SDRA), sepsis y shock séptico y fracaso multiorgánico. Este documento de consenso se ha preparado sobre directrices basadas en evidencia desarrolladas por un panel multidisciplinario de profesionales médicos de cuatro sociedades científicas españolas (Sociedad Española de Medicina Intensiva y Unidades Coronarias [SEMICYUC], Sociedad Española de Neumología y Cirugía Torácica [SEPAR], Sociedad Española de Urgencias y Emergencias [SEMES], Sociedad Española de Anestesiología, Reanimación y Terapéutica del Dolor [SEDAR]) con experiencia en el manejo clínico de pacientes con COVID-19 y otras infecciones virales, incluido el SARS, así como en sepsis y SDRA. El documento proporciona recomendaciones clínicas para el soporte respiratorio no invasivo (ventilación no invasiva, oxigenoterapia de alto flujo con cánula nasal) en cualquier paciente con presentación sospechada o confirmada de COVID-19 con insuficiencia respiratoria aguda. Esta guía de consenso debe servir como base para una atención optimizada y garantizar la mejor posibilidad de supervivencia, así como permitir una comparación fiable de las futuras intervenciones terapéuticas de investigación que formen parte de futuros estudios observacionales o de ensayos clínicos


Coronavirus disease 2019 (COVID-19) is a respiratory tract infection caused by a newly emergent coronavirus, that was first recognized in Wuhan, China, in December 2019. Currently, the World Health Organization (WHO) has defined the infection as a global pandemic and there is a health and social emergency for the management of this new infection. While most people with COVID-19 develop only mild or uncomplicated illness, approximately 14% develop severe disease that requires hospitalization and oxygen support, and 5% require admission to an intensive care unit. In severe cases, COVID-19 can be complicated by the acute respiratory distress syndrome (ARDS), sepsis and septic shock, and multiorgan failure. This consensus document has been prepared on evidence-informed guidelines developed by a multidisciplinary panel of health care providers from four Spanish scientific societies (Spanish Society of Intensive Care Medicine [SEMICYUC], Spanish Society of Pulmonologists [SEPAR], Spanish Society of Emergency [SEMES], Spanish Society of Anesthesiology, Reanimation, and Pain [SEDAR]) with experience in the clinical management of patients with COVID-19 and other viral infections, including SARS, as well as sepsis and ARDS. The document provides clinical recommendations for the noninvasive respiratory support (noninvasive ventilation, high flow oxygen therapy with nasal cannula) in any patient with suspected or confirmed presentation of COVID-19 with acute respiratory failure. This consensus guidance should serve as a foundation for optimized supportive care to ensure the best possible chance for survival and to allow for reliable comparison of investigational therapeutic interventions as part of randomized controlled trials


Subject(s)
Humans , Adult , Coronavirus Infections/complications , Severe acute respiratory syndrome-related coronavirus/pathogenicity , Pneumonia, Viral/therapy , Noninvasive Ventilation/methods , Severe Acute Respiratory Syndrome/therapy , Consensus , Practice Patterns, Physicians' , Pandemics , Administration, Inhalation , Administration, Intranasal/methods , Communicable Disease Control/methods
4.
Rev. esp. anestesiol. reanim ; 67(5): 261-270, mayo 2020. ilus, tab
Article in Spanish | IBECS | ID: ibc-187650

ABSTRACT

La enfermedad por coronavirus 2019 (COVID-19) es una infección del tracto respiratorio causada por un nuevo coronavirus emergente que se reconoció por primera vez en Wuhan, China, en diciembre de 2019. Actualmente la Organización Mundial de la Salud (OMS) ha definido la infección como pandemia y existe una situación de emergencia sanitaria y social para el manejo de esta nueva infección. Mientras que la mayoría de las personas con COVID-19 desarrollan solo una enfermedad leve o no complicada, aproximadamente el 14% desarrollan una enfermedad grave que requiere hospitalización y oxígeno, y el 5% pueden requerir ingreso en una Unidad de Cuidados Intensivos. En casos severos, COVID-19 puede complicarse por el síndrome de dificultad respiratoria aguda (SDRA), sepsis y shock séptico y fracaso multiorgánico. Este documento de consenso se ha preparado sobre directrices basadas en evidencia desarrolladas por un panel multidisciplinario de profesionales médicos de cuatro sociedades científicas españolas (Sociedad Española de Medicina Intensiva y Unidades Coronarias [SEMICYUC], Sociedad Española de Neumología y Cirugía Torácica [SEPAR], Sociedad Española de Urgencias y Emergencias [SEMES], Sociedad Española de Anestesiología, Reanimación y Terapéutica del Dolor [SEDAR]) con experiencia en el manejo clínico de pacientes con COVID-19 y otras infecciones virales, incluido el SARS, así como en sepsis y SDRA. El documento proporciona recomendaciones clínicas para el soporte respiratorio no invasivo (ventilación no invasiva, oxigenoterapia de alto flujo con cánula nasal) en cualquier paciente con presentación sospechada o confirmada de COVID-19 con insuficiencia respiratoria aguda. Esta guía de consenso debe servir como base para una atención optimizada y garantizar la mejor posibilidad de supervivencia, así como permitir una comparación fiable de las futuras intervenciones terapéuticas de investigación que formen parte de futuros estudios observacionales o de ensayos clínicos


Coronavirus disease 2019 (COVID-19) is a respiratory tract infection caused by a newly emergent coronavirus, that was first recognized in Wuhan, China, in December 2019. Currently, the World Health Organization (WHO) has defined the infection as a global pandemic and there is a health and social emergency for the management of this new infection. While most people with COVID-19 develop only mild or uncomplicated illness, approximately 14% develop severe disease that requires hospitalization and oxygen support, and 5% require admission to an intensive care unit. In severe cases, COVID-19 can be complicated by the acute respiratory distress syndrome (ARDS), sepsis and septic shock, and multiorgan failure. This consensus document has been prepared on evidence-informed guidelines developed by a multidisciplinary panel of health care providers from four Spanish scientific societies (Spanish Society of Intensive Care Medicine [SEMICYUC], Spanish Society of Pulmonologists [SEPAR], Spanish Society of Emergency [SEMES], Spanish Society of Anesthesiology, Reanimation, and Pain [SEDAR]) with experience in the clinical management of patients with COVID-19 and other viral infections, including SARS, as well as sepsis and ARDS. The document provides clinical recommendations for the noninvasive respiratory support (noninvasive ventilation, high flow oxygen therapy with nasal cannula) in any patient with suspected or confirmed presentation of COVID-19 with acute respiratory failure. This consensus guidance should serve as a foundation for optimized supportive care to ensure the best possible chance for survival and to allow for reliable comparison of investigational therapeutic interventions as part of randomized controlled trials


Subject(s)
Humans , Adult , Coronavirus Infections/complications , Severe acute respiratory syndrome-related coronavirus/pathogenicity , Pneumonia, Viral/therapy , Noninvasive Ventilation/methods , Severe Acute Respiratory Syndrome/therapy , Consensus , Practice Patterns, Physicians' , Pandemics , Administration, Inhalation , Administration, Intranasal/methods , Communicable Disease Control/methods
5.
Rev Esp Anestesiol Reanim (Engl Ed) ; 67(5): 261-270, 2020 May.
Article in English, Spanish | MEDLINE | ID: mdl-32307151

ABSTRACT

Coronavirus disease 2019 (COVID-19) is a respiratory tract infection caused by a newly emergent coronavirus, that was first recognized in Wuhan, China, in December 2019. Currently, the World Health Organization (WHO) has defined the infection as a global pandemic and there is a health and social emergency for the management of this new infection. While most people with COVID-19 develop only mild or uncomplicated illness, approximately 14% develop severe disease that requires hospitalization and oxygen support, and 5% require admission to an intensive care unit. In severe cases, COVID-19 can be complicated by the acute respiratory distress syndrome (ARDS), sepsis and septic shock, and multiorgan failure. This consensus document has been prepared on evidence-informed guidelines developed by a multidisciplinary panel of health care providers from four Spanish scientific societies (Spanish Society of Intensive Care Medicine [SEMICYUC], Spanish Society of Pulmonologists [SEPAR], Spanish Society of Emergency [SEMES], Spanish Society of Anesthesiology, Reanimation, and Pain [SEDAR]) with experience in the clinical management of patients with COVID-19 and other viral infections, including SARS, as well as sepsis and ARDS. The document provides clinical recommendations for the noninvasive respiratory support (noninvasive ventilation, high flow oxygen therapy with nasal cannula) in any patient with suspected or confirmed presentation of COVID-19 with acute respiratory failure. This consensus guidance should serve as a foundation for optimized supportive care to ensure the best possible chance for survival and to allow for reliable comparison of investigational therapeutic interventions as part of randomized controlled trials.


Subject(s)
Coronavirus Infections/therapy , Noninvasive Ventilation/methods , Pneumonia, Viral/therapy , Respiratory Distress Syndrome/diagnosis , Betacoronavirus , COVID-19 , Consensus , Coronavirus Infections/complications , Coronavirus Infections/diagnosis , Humans , Pandemics , Pneumonia, Viral/complications , Pneumonia, Viral/diagnosis , Practice Guidelines as Topic , Respiratory Distress Syndrome/etiology , SARS-CoV-2
6.
Article in English, Spanish | MEDLINE | ID: mdl-31174905

ABSTRACT

INTRODUCTION AND AIMS: Achalasia is characterized by incomplete relaxation of the lower esophageal sphincter and esophageal aperistalsis. The efficacy of peroral endoscopic myotomy (POEM) is similar to that of the Heller myotomy, with an apparently greater prevalence of gastroesophageal reflux disease. Our aim was to determine the presence of GERD in a post-POEM cohort of Mexican patients with achalasia and follow-up of at least 12 months. MATERIALS AND METHODS: A retrospective cohort study was conducted on post-POEM patients with a minimum of 12 months of follow-up, within the time frame of 2012 to 2017. Pregnant patients were excluded. Serial endoscopy, pH study, and GERDQ application were performed. Univariate and bivariate data analyses were carried out and statistical significance was set at a P<0.05. RESULTS: Sixty-eight patients had post-POEM follow-up for 12 months. Of those patients, follow-up continued to 24 months for 58, 36 months for 47, 48 months for 39, and 60 months for 25. Mean patient age was 47.8±14.3 years, 57.3% of the patients were women, 77.9% were treatment-naïve, and 54.4% had type II achalasia. The pH study, endoscopy, and questionnaire were positive in 73, 28, and 18% at 3 months; 48, 35, and 13% at 6 months, and 55, 30, and 15% at 12 months, respectively. Once the proton pump inhibitor was begun, the percentages decreased to 5, 2, and 6% at 24 months; 6, 2, and 8% at 36 months; 4,1, and 6% at 48 months; and 3, 1, and 4% at 60 months, respectively. There was no relation between the efficacy of POEM and the presence or intensity of GERD. There were no secondary complications due to gastroesophageal reflux. CONCLUSIONS: The post-POEM prevalence of GERD was 50% in the short term (12 months), with no evidence of complications at the medium term or long term (60 months). Gastroesophageal reflux was adequately controlled through proton pump inhibitors administration in over 95% of the cases.


Subject(s)
Esophageal Achalasia/surgery , Gastroesophageal Reflux/etiology , Postoperative Complications , Pyloromyotomy , Adult , Aged , Female , Follow-Up Studies , Gastroesophageal Reflux/drug therapy , Gastroesophageal Reflux/epidemiology , Humans , Male , Middle Aged , Postoperative Complications/drug therapy , Postoperative Complications/epidemiology , Prevalence , Proton Pump Inhibitors/therapeutic use , Retrospective Studies , Treatment Outcome
7.
Rev Gastroenterol Mex (Engl Ed) ; 84(3): 372-397, 2019.
Article in English, Spanish | MEDLINE | ID: mdl-31213326

ABSTRACT

INTRODUCTION: Non-cardiac chest pain is defined as a clinical syndrome characterized by retrosternal pain similar to that of angina pectoris, but of non-cardiac origin and produced by esophageal, musculoskeletal, pulmonary, or psychiatric diseases. AIM: To present a consensus review based on evidence regarding the definition, epidemiology, pathophysiology, and diagnosis of non-cardiac chest pain, as well as the therapeutic options for those patients. METHODS: Three general coordinators carried out a literature review of all articles published in English and Spanish on the theme and formulated 38 initial statements, dividing them into 3 main categories: (i)definitions, epidemiology, and pathophysiology; (ii)diagnosis, and (iii)treatment. The statements underwent 3rounds of voting, utilizing the Delphi system. The final statements were those that reached >75% agreement, and they were rated utilizing the GRADE system. RESULTS AND CONCLUSIONS: The final consensus included 29 statements. All patients presenting with chest pain should initially be evaluated by a cardiologist. The most common cause of non-cardiac chest pain is gastroesophageal reflux disease. If there are no alarm symptoms, the initial approach should be a therapeutic trial with a proton pump inhibitor for 2-4weeks. If dysphagia or alarm symptoms are present, endoscopy is recommended. High-resolution manometry is the best method for ruling out spastic motor disorders and achalasia and pH monitoring aids in demonstrating abnormal esophageal acid exposure. Treatment should be directed at the pathophysiologic mechanism. It can include proton pump inhibitors, neuromodulators and/or smooth muscle relaxants, psychologic intervention and/or cognitive therapy, and occasionally surgery or endoscopic therapy.


Subject(s)
Chest Pain/therapy , Chest Pain/diagnosis , Consensus , Humans , Mexico
8.
Article in English, Spanish | MEDLINE | ID: mdl-29496268

ABSTRACT

INTRODUCTION AND AIMS: Achalasia is characterized by the absence of lower esophageal sphincter relaxation and esophageal aperistalsis. Diagnosis is confirmed through high-resolution esophageal manometry. Laparoscopic myotomy is the standard treatment, but peroral endoscopic myotomy (POEM) is a safe and effective alternative, with good short-term and medium-term results. Our aim was to describe the short-term and medium-term experience with POEM at a tertiary care center. MATERIALS AND METHODS: The study was conducted within the time frame of November 2014 and February 2017. Treatment-naïve achalasia patients and previously-treated achalasia patients that were candidates for POEM were included. A protocolized 24-month follow-up was carried out. RESULTS: Fifty procedures were included and 31 (68%) were performed on women. Forty-one (82%) of the procedures were carried out on previously untreated patients, 7 (14%) were performed on previously treated patients, and 2 (4%) of the patients had redo-POEM. The mean age of the patients was 48.8±14.1 years. The pre-POEM Eckardt score was 9 and the integrated relaxation pressure was 24.4mmHg. Sixty-eight percent of the patients had type ii achalasia. Procedure time was 80min and myotomy length was 12.6cm. Hospital stay was 3 days and subcutaneous emphysema was the most common adverse event (30%). A total of 22/50 (44%) patients reached the 24-month follow-up, maintaining the Eckardt score and the decrease in the integrated relaxation pressure. There were no deaths. A total of 47.5% of the patients had a positive pH-study at 6 months, 15% had clinical reflux, and 35% presented with mild esophagitis. All the patients were adequately controlled with proton pump inhibitors. CONCLUSION: POEM is safe and effective in the short term and medium term for the treatment of achalasia and other esophageal motor disorders in Mexican patients.


Subject(s)
Esophageal Achalasia/surgery , Esophageal Motility Disorders/surgery , Myotomy/methods , Natural Orifice Endoscopic Surgery/methods , Adult , Aged , Female , Humans , Male , Mexico , Middle Aged , Tertiary Care Centers , Treatment Outcome
9.
Rev Esp Quimioter ; 31(6): 532-536, 2018 Dec.
Article in Spanish | MEDLINE | ID: mdl-30364925

ABSTRACT

OBJECTIVE: Spontaneous bacterial peritonitis (SBP) is a frequent and severe entity in patients with cirrhosis or ascites due to other causes. However, Listeria monocytogenes is a microorganism that has been scarcely identified as a causative agent of SBP. METHODS: In this study, a descriptive analysis of cases of L. monocytogenes SBP was carried out in our center for 26 years (1992-2017). RESULTS: A total of eight patients were diagnosed, with an average age of 58 years, with no differences in sex distribution and all of them were community acquired cases. Half of the patients had underlying liver disease, two of them active malignancies; one was undergoing continuous ambulatory peritoneal dialysis and the last one with hypertensive heart disease. Six (75%) of the patients received a third-generation cephalosporin as empirical treatment. The clinical course was favorable after receiving directed antibiotic treatment in five (62.5%) of the patients. However, three of them, under the age of 59, died. Serotyping of L. monocytogenes isolates revealed that half of them were serovar 4, two 1 / 2a and the remaining one 1 / 2c. All strains were susceptible to ampicillin, meropenem, erythromycin and cotrimoxazole. CONCLUSIONS: We conclude by emphasizing the importance of taking this etiology into account in patients with underlying liver disease and with clinical or laboratory data suggesting SBP, mainly due to the need for specific antibiotic treatment different from conventionally empirically used.


Subject(s)
Listeria monocytogenes , Listeriosis/microbiology , Peritonitis/microbiology , Adult , Aged , Aged, 80 and over , Anti-Bacterial Agents/pharmacology , Anti-Bacterial Agents/therapeutic use , Cephalosporins/therapeutic use , Community-Acquired Infections/microbiology , Female , Humans , Listeriosis/drug therapy , Liver Diseases/drug therapy , Liver Diseases/microbiology , Male , Microbial Sensitivity Tests , Middle Aged , Peritonitis/drug therapy
10.
Rev Gastroenterol Mex (Engl Ed) ; 83(2): 168-189, 2018.
Article in English, Spanish | MEDLINE | ID: mdl-29555103

ABSTRACT

INTRODUCTION: Significant advances have been made in the knowledge and understanding of the epidemiology, pathophysiology, diagnosis, and treatment of chronic constipation, since the publication of the 2011 guidelines on chronic constipation diagnosis and treatment in Mexico from the Asociación Mexicana de Gastroenterología. AIMS: To present a consensus review of the current state of knowledge about chronic constipation, providing updated information and integrating the new scientific evidence. METHODS: Three general coordinators reviewed the literature published within the time frame of January 2011 and January 2017. From that information, 62 initial statements were formulated and then sent to 12 national experts for their revision. The statements were voted upon, using the Delphi system in 3 voting rounds (2 electronic and one face-to-face). The statements were classified through the GRADE system and those that reached agreement >75% were included in the consensus. RESULTS AND CONCLUSIONS: The present consensus is made up of 42 final statements that provide updated knowledge, supplementing the information that had not been included in the previous guidelines. The strength of recommendation and quality (level) of evidence were established for each statement. The current definitions of chronic constipation, functional constipation, and opioid-induced constipation are given, and diagnostic strategies based on the available diagnostic methods are described. The consensus treatment recommendations were established from evidence on the roles of diet and exercise, fiber, laxatives, new drugs (such as prucalopride, lubiprostone, linaclotide, plecanatide), biofeedback therapy, and surgery.


Subject(s)
Constipation/diagnosis , Constipation/therapy , Chronic Disease , Combined Modality Therapy , Constipation/epidemiology , Delphi Technique , Humans , Mexico/epidemiology
12.
Dermatol Online J ; 24(9)2018 Sep 15.
Article in English | MEDLINE | ID: mdl-30677836

ABSTRACT

La aplasia cutis congénita es una rara alteración caracterizada por la ausencia de áreas localizadas de piel en el momento del nacimiento. Suele manifestarse como una lesión solitaria localizada principalmente en el cuero cabelludo, que puede estar asociada con otras malformaciones congénitas. Las complicaciones pueden ser fatales, por lo que es necesario un tratamiento individualizado que vendrá determinado por el tamaño, localización y grado de afectación de estructuras subyacentes. Presentamos un caso de aplasia cutis congénita del cuero cabelludo con múltiples lesiones y defecto óseo subyacente de 3 × 1.5 cm de tamaño, pero sin otras anomalías asociadas. El manejo conservador permitió una adecuada y completa epitelización cutánea con cierre del defecto óseo subyacente sin necesidad de procedimientos invasivos.


Subject(s)
Bone Diseases, Developmental/diagnosis , Bone Diseases, Developmental/therapy , Ectodermal Dysplasia/diagnosis , Ectodermal Dysplasia/therapy , Conservative Treatment , Female , Humans , Infant, Newborn , Musculoskeletal Abnormalities/diagnosis , Musculoskeletal Abnormalities/therapy , Skull/abnormalities
13.
Article in Spanish | LILACS | ID: biblio-963942

ABSTRACT

El presente trabajo forma parte del plan de beca de maestría "Aportes del psicoanálisis al abordaje de las toxicomanías", enmarcado en el proyecto UBACyT 2014-2017: "Operadores conceptuales de la segunda tópica freudiana: alcances y límites" (Laznik, 2014). Entendiendo que el modo de recortar el objeto de estudio supone ya una toma de posición y un modo de pensar la dirección de la cura, este artículo se propone situar las dificultades que la definición de la noción de toxicomanía presenta para la teoría psicoanalítica.


This article is part of the master plan "Contributions of psychoanalysis to addressing drug addiction ", set in the 2014-2017 UBACyT project: "Conceptual operators of the second Freudian topography: scope and limits" (Laznik, 2014). Understanding that the way in which the object of study is outlined involves taking a stand as well as a particular way of understanding the direction of the treatment, this article intends to place the difficulties that the definition of the concept of addiction presents for psychoanalytic theory.


Subject(s)
Humans , Psychoanalytic Theory , Substance Abuse Detection , Substance-Related Disorders/diagnosis
14.
Rev Gastroenterol Mex ; 81(3): 149-67, 2016.
Article in English, Spanish | MEDLINE | ID: mdl-26976238

ABSTRACT

BACKGROUND: Since the publication in 2009 of the Guidelines on the Diagnosis and Treatment of Irritable Bowel Syndrome of the Asociación Mexicana de Gastroenterología (2009 Guidelines), there have been significant advances in our knowledge of the epidemiology, pathophysiology, diagnosis, and treatment of this disease. AIMS: To present a consensus review of the most current knowledge of IBS, updating the 2009 Guidelines by incorporating new internationally published scientific evidence, with a special interest in Mexican studies. METHODS: The PubMed literature from January 2009 to March 2015 was reviewed and complemented through a manual search. Articles in English and Spanish were included and preference was given to consensuses, guidelines, systematic reviews, and meta-analyses. Statements referring to the different aspects of the disease were formulated and voted upon by 24 gastroenterologists employing the Delphi method. Once a consensus on each statement was reached, the quality of evidence and strength of recommendation were determined through the GRADE system. RESULTS: Forty-eight statements were formulated, updating the information on IBS and adding the complementary data that did not appear in the 2009 Guidelines regarding the importance of exercise and diet, diagnostic strategies, and current therapy alternatives that were analyzed with more stringent scientific vigor or that emerged within the last 5 years. CONCLUSIONS: We present herein a consensus review of the most relevant advances in the study of IBS, updating and complementing the 2009 Guidelines. Several studies conducted in Mexico were included.


Subject(s)
Irritable Bowel Syndrome/therapy , Consensus , Delphi Technique , Evidence-Based Medicine , Guidelines as Topic , Humans , Mexico
15.
Rev Gastroenterol Mex ; 80(2): 121-9, 2015.
Article in English, Spanish | MEDLINE | ID: mdl-26148745

ABSTRACT

INTRODUCTION: Non-cardiac chest pain (NCCP) is mainly related to oesophageal disease, and in spite of being a common condition in Mexico, information regarding it is scarce. AIM: To assess the clinical characteristics and health-related quality of life of patients with NCCP of presumed oesophageal origin. MATERIAL AND METHODS: Patients with NCCP of presumed oesophageal origin with no previous treatment were included in the study. Associated symptoms were assessed and upper gastrointestinal endoscopy and 24-hour oesophageal pH monitoring were performed to diagnose gastroesophageal reflux disease, while oesophageal manometry was used to determine oesophageal motility disorders. The SF-36 Health-Related Quality of Life (HR-QoL) questionnaire was completed and its results compared to a control group without oesophageal symptoms. RESULTS: The study included 33 patients, of which 61% were women, and the mean age was 46.1 (±11.6) years. Causes of NCCP were gastroesophageal reflux disease in 48%, achalasia in 34%, and functional chest pain in 18%. The average progression time for chest pain was 24 (2-240) months, with ≤ 3 events/week in 52% of the patients. The most frequent accompanying symptoms were: regurgitation (81%), dysphagia (72%) and heartburn (66%). Patients with NCCP show deterioration in HR-QoL compared to the control group (P=.01), regardless of chest pain aetiology. The most affected areas were general perception of health, emotional issues, and mental health sub-scale (P>0.05). CONCLUSIONS: In our population, patients with NCCP show deterioration in HR-QoL regardless of the aetiology, frequency, and accompanying symptoms.


Subject(s)
Chest Pain/etiology , Esophageal Motility Disorders/diagnosis , Gastroesophageal Reflux/diagnosis , Quality of Life , Adult , Case-Control Studies , Esophageal Motility Disorders/complications , Esophageal pH Monitoring , Esophagoscopy , Female , Gastroesophageal Reflux/complications , Health Status Indicators , Humans , Male , Manometry , Mexico , Middle Aged
17.
Enferm. nefrol ; 17(1): 22-27, ene.-mar. 2014. tab, graf
Article in Spanish | IBECS | ID: ibc-182951

ABSTRACT

El uso de catéteres centrales ha aumentando de forma importante a pesar de su mayor morbi-mortalidad en comparación con las FAV. Las principales complicaciones son trombosis, bacteriemia-sepsis y limitación de la eficacia dialítica disminuyendo la calidad de vida de los pacientes y elevando el coste sanitario. En nuestra unidad, el sellado se realizaba con heparina sódica al 5% y actualmente utilizamos TauroLockTM Hep 500(R), compuesta de (ciclo)-taurolidina (agente antimicrobiano biocompatible), citrato al 4% y heparina 500 UI/ml. Objetivo: comprobar la eficacia del Taurolock para reducir la incidencia de colonización intraluminal y trombosis al compararla con heparina sódica al 5%. Material y método: realizamos un estudio observacional longitudinal de cohorte y analizamos colonización intraluminal, trombosis, biofilm y uso de antibioterapia. Resultados: observamos mejoría en la permeabilidad del catéter, disminución del uso de urokinasa, reducción de sesiones en unipunción y del uso de antibiótico. Conclusiones: nuestro estudio muestra que el sellado del catéter para hemodiálisis con una solución que contiene taurolidina como antimicrobiano puede reducir significativamente la incidencia de sepsis relacionada con el catéter. La taurolidina parece se efectiva y segura y no conlleva riesgos ni efectos secundarios. La adicción de 500 ui de heparina a la solución de sellado junto con citrato al 4% ha disminuido los eventos trombóticos reduciendo el uso de fibrilolíticos y el uso de unipunción totalmente, presentando una mejoría de la eficacia dialítica


The use of central catheters has increased significantly despite their greater morbi-mortality compared to AVF. The main complications are thrombosis, bacteriaemiasepsis, and limitation of dialysis efficacy, reducing quality of life for patients and increasing the healthcare cost. In our unit, 5% heparin sodium was previously used as lock solution and we currently use TauroLockTM Hep 500(R), composed of (cyclo)-taurolidine (biocompatible antimicrobial agent) 4% citrate and heparin 500 UI/ml. Objective: to verify the efficacy of Taurolock in reducing the incidence of intraluminal colonization and thrombosis compared with 5% heparin sodium. Material and method: we carried out a longitudinal observational cohort study and we analysed intraluminal colonization, thrombosis, biofilm and use of antibiotherapy. Results: we observed an improvement in catheter permeability, a reduction in the use of urokinase, reduction in unipuncture sessions and in use of antibiotic. Conclusions: our study shows that using a lock solution that contains taurolidine as an antimicrobial agent for haemodialysis catheters can significantly reduce the incidence of catheter-related sepsis. Taurolidine appears to be effective and safe and does not entail risks or side effects. The addition of 500 iu of heparin to the lock solution together with 4% citrate has reduced thrombotic events by reducing the use of fibrilolytics and eliminating completely the use of unipuncture, presenting an improvement in dialysis efficacy


Subject(s)
Humans , Catheterization/standards , Catheter Obstruction/statistics & numerical data , Central Venous Catheters/statistics & numerical data , Anticoagulants/therapeutic use , Hemostatics/analysis , Catheter-Related Infections/prevention & control , Catheters, Indwelling/adverse effects , Heparin/therapeutic use , Renal Dialysis/methods , Renal Insufficiency, Chronic/therapy
18.
An Pediatr (Barc) ; 81(2): 115-9, 2014 Aug.
Article in Spanish | MEDLINE | ID: mdl-24286885

ABSTRACT

INTRODUCTION: The prevalence of ankyloglossia has been estimated at around 4% of live births. Its prevalence at national level is unknown. MATERIAL AND METHODS: Multicenter, prospective observational study. Six hospitals in Asturias took part. All newborns were examined on Sundays, Tuesdays and Thursdays for 3 months. Coryllos and Hazelbaker criteria were used to diagnose ankyloglossia. RESULTS: The prevalence in the 667 newborns examined was 12.11% (95% CI: 9.58 to 14.64), of whom 62% were male. One in 4 children with ankyloglossia had a family history. According to Coryllos' classification, type II was the most common (54%). CONCLUSIONS: The prevalence of ankyloglossia in Asturias was 2 to t3 times higher than expected. The diagnostic criteria for ankyloglossia needs to be unified, and further studies are required to determine the association with breastfeeding difficulties and other health problems.


Subject(s)
Mouth Abnormalities/epidemiology , Ankyloglossia , Female , Humans , Infant, Newborn , Longitudinal Studies , Male , Prevalence , Prospective Studies , Spain/epidemiology
19.
Rev Gastroenterol Mex ; 77 Suppl 1: 47-9, 2012 Aug.
Article in Spanish | MEDLINE | ID: mdl-22939480
20.
Rev Gastroenterol Mex ; 76(3): 231-6, 2011.
Article in English | MEDLINE | ID: mdl-22041312

ABSTRACT

INTRODUCTION: Data regarding the age impact on the clinical presentation and esophageal motility in adults with idiopathic achalasia are scarce. OBJECTIVE: To asses the clinical and manometric features of elderly patients with idiopathic achalasia. METHODS: The medical charts of 159 patients diagnosed with achalasia were divided into two groups according to the patients' age: ?60 years (n = 123) and >60 years (n = 36). Clinical and manometric findings [esophageal body aperistalsis, basal lower esophageal sphincter (LES) pressure and abnormal LES relaxation] of both groups were compared upon diagnosis. Patients with previous esophageal interventions were excluded. RESULTS: Only chest pain was more common in the ?60 year-old group (51.2% vs. 22.2%, p <0.003). This difference remained when comparing the group of men ≤60 years. Other presenting features (including sex, weight loss, and presence of dysphagia, regurgitation and heartburn) did not differ between the groups. The LES relaxation was incomplete in 70.4% of the cases. No differences on the basal LES pressure, residual LES pressure or the amplitude of the esophageal body contractions between both groups were found. Considering only the classic achalasia cases, symptomatic time before diagnosis was greater in ≤60 years compared with older patients: 24 vs. 12 months (p <0.05), respectively. CONCLUSIONS: These results suggest that chest pain is more common in younger male achalasia patients and residual LES pressure decreases with age.


Subject(s)
Esophageal Achalasia/diagnosis , Esophageal Achalasia/physiopathology , Manometry , Adult , Aged , Female , Humans , Male , Middle Aged , Retrospective Studies
SELECTION OF CITATIONS
SEARCH DETAIL
...